BioXcel Therapeutics Inc To Discuss The Data Results From The Phase 2 Trial of BXCL701 Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Congrats on the data. I wanted to ask about the avelumab historical control you use here. Can you help us understand how the study was chosen and why it's a fair comparator for this indication and for your trial?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Congrats on the data. Just a couple from my side. Bigger picture to start. I guess after the prior updates on this asset, you had said a couple of times that -- the data with FDA. I'm just curious, did this happen? And if so, just what was the outcome of those discussions? And then secondly, can you just describe the intellectual property, sort of, portfolio for 701, so we can think about that, especially in terms of monetizing this?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : It's a 2 parter. So you put these results into context with the avelumab data set, but could you give us a sense of where exactly an innate immunity activator 701 lies in the competitive landscape for neuroendocrine prostate cancer? And what that might mean for next steps, specifically in terms of potential competition for patients for a Phase IIb trial? And how much time would a typical Phase IIb trial take for this kind of indication?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : That was on -- you mentioned the time line for a potentially infeasible trial, but what would a feasible Phase IIb -- would look like?